GILD Trading Analysis - 10/23/2026 04:56 PM — TRU-SENTIMENT

News Headlines & Context

The following items reflect general knowledge context only and are separated from the data-driven analysis below:

• Gilead Sciences (GILD) recently reported progress in its HIV prevention franchise, with continued uptake of lenacapavir-based therapies cited in industry briefings.
• Analysts have noted upcoming patent cliff considerations for legacy antiviral products through late 2026 as a moderate overhang.
• GILD declared its regular quarterly dividend with ex-dividend date of 2026-09-15, supporting its income-profile appeal.
• No major earnings catalyst is scheduled in the immediate embedded window; next fiscal year end per data is 2025-12-01.
• Broad biotech sector momentum has been constructive, which may align with the bullish options flow observed in the embedded sentiment data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E is 17.70; trailing EPS is -2.60, indicating the company is currently showing negative trailing earnings.
• Dividend yield is 2.10% with a dividend rate of 3.28 and ex-dividend date of 2026-09-15.
• Market cap is 193,482,578,200.00 with shares outstanding of 1,239,955,000.00.
• Beta is 0.03, suggesting very low systematic volatility relative to the market.
• 52-week high is 160.51 and 52-week low is 114.02; current price of 156.85 is near the upper bound.
• Institutional ownership is 67.61%.
• PEG ratio, forward P/E, forward EPS, price-to-book, total revenue, revenue growth, ROE, profit margins, debt-to-equity, and free cash flow are all null in the data.
• Analyst consensus and target mean price are null; no analyst opinion count provided.
• Fundamentals show a low-beta large-cap with negative trailing EPS but a paying dividend; this diverges from the strong bullish technical and options flow picture which is price/momentum driven.

Current Market Position

Current price per indicators is 156.85. From daily history, the stock closed at 156.85 on 2026-10-23 after trading between 155.76 and 157.65. On 2026-10-22 it closed at 156.73 (range 153.00 to 157.42). The 30-day range per indicators is high 160.51 and low 142.60.

Minute bars show the session starting 2026-10-22 at 09:30 with open 154.24, low 153.00, then climbing to 155.82 by 09:50. The final bars on 2026-10-23 show a fade from 157.11 at 15:35 to 156.13 at 15:55 on rising volume (336,213), indicating late-session selling pressure intraday.

Technical Analysis

• Price is above SMA 5 (155.53), SMA 20 (151.02), and SMA 50 (148.83) — bullish alignment, no bearish crossover.
• RSI 14 at 69.49 shows strong momentum but near overbought (above 70 threshold).
• MACD (2.58) above signal (2.07) with positive histogram (0.52) confirms bullish momentum.
• Bollinger Bands: price 156.85 is between middle (151.02) and upper (159.91); no squeeze, mild expansion.
• 30-day range: price at 156.85 is near top (range 142.60 to 160.51), approx 87% of range.

True Sentiment Analysis (Delta 40-60 Options)

Per embedded True Sentiment data for 2026-10-23:

Call Dollar Volume: 579,905.00 (63.80%) Put Dollar Volume: 328,810.00 (36.20%) Total: 908,715.00

• Sentiment is Bullish with 567 call contracts vs 317 put contracts.
• Call trades 36 vs put trades 14 show stronger directional conviction on call side.
• Only 3.80% of total options analyzed (50 of 1,328) met delta 40-60 filter — pure directional flow leans bullish.
• No divergence from technicals; both price and options flow signal bullish near-term expectation.

Key Price Levels (Observational Only)